Filtered By:
Procedure: Hemodialysis
Therapy: Dialysis

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 299 results found since Jan 2013.

Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis.
CONCLUSIONS: -More dialysis patients are being started on dabigatran and rivaroxaban, even when their use is contraindicated and there are no studies to support the benefits outweigh the risks of these drugs in ESRD. PMID: 25595139 [PubMed - as supplied by publisher]
Source: Circulation - January 16, 2015 Category: Cardiology Authors: Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW Tags: Circulation Source Type: research

Effects of Sleepiness on Survival in Japanese Hemodialysis Patients: J-DOPPS Study
Sleep disorder and poor sleep quality are common in chronic hemodialysis (HD) patients. They have been claimed as a cause of morbidity and mortality. The relationship between the degree of sleepiness and survival has not been studied. We studied the degree of sleepiness in 1,252 adult HD patients (age ≥20 years) recruited into the Dialysis Outcomes Practice Pattern Study in Japan (J-DOPPS III), using the Japanese version of the Epworth Sleepiness Scale (JESS) questionnaire. Demographic data were presented for three subgroups: low, intermediate, and high JESS score. Cox proportional hazard regression analysis was performe...
Source: Nephron Clinical Practice - January 8, 2015 Category: Urology & Nephrology Source Type: research

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
In conclusion, based on these single-dose PK data, a supplementary dose of edoxaban may not be required following a haemodialysis session. Importantly, haemodialysis is not an effective mechanism for removal of edoxaban from the blood. PMID: 25566930 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 8, 2015 Category: Hematology Authors: Parasrampuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha PK, He L, Dishy V, Brown KS Tags: Thromb Haemost Source Type: research

Non Invasive Evaluation of Cardiac Hemodynamics in End Stage Renal Disease (ESRD)
Conclusions Blood pressure, cardiac morphology and function are significantly modified by acute volume depletion and such variations are strictly interrelated. SW and LVEDd/height2.7 may identify ESRD patients carrying an higher volume load.
Source: High Blood Pressure and Cardiovascular Prevention - November 19, 2014 Category: Cardiology Source Type: research

Treatment with Haemodiafiltration Stabilises Vascular Stiffness (Measured by Aortic Pulse Wave Velocity) Compared to Haemodialysis
Background/Aims: Cerebrovascular diseases such as stroke are increased in dialysis patients, and haemodiafiltration has been reported to reduce cerebrovascular mortality compared to haemodialysis. We wished to determine whether haemodiafiltration improves arterial stiffness. Methods: We audited aortic pulse wave velocity (PWV) measurements 6 months apart in 3 cohorts of patients: 69 treated with haemodialysis, 78 who converted from haemodialysis to haemodiafiltration and 142 treated with haemodiafiltration. Results: Cohorts were well matched for age (means ± SD: haemodialysis 64 ± 15 years vs. haemodialysis to haemodiafi...
Source: Nephron Clinical Practice - November 7, 2014 Category: Urology & Nephrology Source Type: research

Changes in Volumetric Hemodynamic Parameters Induced by Fluid Removal on Hemodialysis in Critically Ill Patients
Abstract Management of volume status is difficult in critically ill patients with renal failure. Volumetric hemodynamic indices are increasingly being used to guide fluid therapy in the intensive care unit (ICU), but are not established to monitor hemodialysis‐induced fluid removal in critically ill patients. Using volumetric hemodynamic monitoring, changes in extravascular lung water index (EVLWI) and intrathoracic blood volume index (ITBVI) were measured immediately before and after hemodialysis sessions in 35 ICU patients. Additional hemodynamic and oxygenation related parameters were recorded at the same time, and on...
Source: Therapeutic Apheresis and Dialysis - September 4, 2014 Category: Hematology Authors: Friederike Compton, Marie Vogel, Walter Zidek, Markus Giet, Timm Westhoff Tags: Original Article Source Type: research

Evidence for the Prevention and Treatment of Stroke in Dialysis Patients.
Abstract The risks of both ischemic and hemorrhagic stroke are particularly high in dialysis patients of any age and outcomes are poor. It is therefore important to identify strategies that safely minimize stroke risk in this population. Observational studies have been unable to clarify the relative importance of traditional stroke risk factors such as blood pressure and cholesterol in those on dialysis, and are affected by biases that usually make them an inappropriate source of data on which to base therapeutic decisions. Well-conducted randomized trials are not susceptible to such biases and can reliably invest...
Source: Seminars in Dialysis - July 7, 2014 Category: Urology & Nephrology Authors: Herrington W, Haynes R, Staplin N, Emberson J, Baigent C, Landray M Tags: Semin Dial Source Type: research

Intracerebral hemorrhage was the highest cause of mortality among stroke subtypes in Japanese dialysis patients
Source: Hemodialysis International - July 1, 2014 Category: Hematology Authors: Minako Wakasugi, Junichiro J. Kazama, Ichiei Narita Tags: Letter to the Editor Source Type: research

Piperacillin/tazobactam‐induced neurotoxicity in a hemodialysis patient: A case report
This report presents a case of a hypertensive and diabetic 67‐year‐old woman in regular hemodialysis, which previously had a stroke. She was hospitalized presenting pneumonia, which was initially treated with cefepime. Two days after treatment, she presented dysarthria, left hemiparesis, ataxia, and IX and X cranial nerves paresis. Computed tomography showed no acute lesions and cefepime neurotoxicity was hypothesized, and the antibiotic was replaced by piperacillin/tazobactam. The neurologic signs disappeared; however, 4 days after with piperacillin/tazobactam treatment, the neurological manifestations returned. A new...
Source: Hemodialysis International - July 1, 2014 Category: Hematology Authors: Precil Diego M. M. Neves, Fernanda M. Freitas, Christiane A. Kojima, Beatriz L. Carmello, Rodrigo Bazan, Pasqual Barretti, Luis C. Martin Tags: Case Report Source Type: research

Therapy of anemia and iron deficiency in dialysis patients: An update.
Abstract The Kidney Disease Improving Global Outcomes (KDIGO)-2012 on the treatment of anemia emit suggestions (which differ from recommendations) based on a scientific evidence of low level. The first rule is no harm; physicians must take into account the profile of the patient and its associated morbidities and remember on the potential risks to begin a treatment by erythropoiesis stimulating agents (ESA) (thrombosis of arteriovenous fistula, hypertension, stroke). All correctable causes of anemia other than erythropoietin deficiency should be actively sought. It is necessary to individualize the treatment by ES...
Source: Nephrologie and Therapeutique - June 26, 2014 Category: Urology & Nephrology Authors: Rostoker G, Hummel A, Chantrel F, Ryckelynck JP Tags: Nephrol Ther Source Type: research

Evidence for the Prevention and Treatment of Stroke in Dialysis Patients
Abstract The risks of both ischemic and hemorrhagic stroke are particularly high in dialysis patients of any age and outcomes are poor. It is therefore important to identify strategies that safely minimize stroke risk in this population. Observational studies have been unable to clarify the relative importance of traditional stroke risk factors such as blood pressure and cholesterol in those on dialysis, and are affected by biases that usually make them an inappropriate source of data on which to base therapeutic decisions. Well‐conducted randomized trials are not susceptible to such biases and can reliably investigate t...
Source: Seminars In Dialysis - May 1, 2014 Category: Hematology Authors: William Herrington, Richard Haynes, Natalie Staplin, Jonathan Emberson, Colin Baigent, Martin Landray Tags: Review Source Type: research

Ischemic and Hemorrhagic Stroke: High Incidence in Hemodialysis and Peritoneal Dialysis Patients
Related Article, p. 604
Source: American Journal of Kidney Diseases - March 27, 2014 Category: Urology & Nephrology Authors: David A. Drew, Mark J. Sarnak Tags: Editorials Source Type: research

Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial
Conclusions Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; ClinicalTrials.gov number: NCT00582114)
Source: Nephrology Dialysis Transplantation - February 28, 2014 Category: Urology & Nephrology Authors: Agarwal, R., Sinha, A. D., Pappas, M. K., Abraham, T. N., Tegegne, G. G. Tags: Intra- and Extracorporeal Treatments of Kidney Failure Source Type: research

Warfarin Use and the Risk for Stroke and Bleeding in Patients with Atrial Fibrillation Undergoing Dialysis.
CONCLUSIONS: Our results suggest that warfarin use is not beneficial in reducing stroke risk but is associated with a higher bleeding risk in patients with AF undergoing dialysis. PMID: 24452752 [PubMed - as supplied by publisher]
Source: Circulation - January 22, 2014 Category: Cardiology Authors: Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L Tags: Circulation Source Type: research

Associations between GSTM1*0 and GSTA1*A genotypes with the risk of cardiovascular death among hemodialyses patients
Conclusions: Combined GSTM1*0/GSTA1*A genotype might be considered as genetic markers for cardiovascular death risk in ESRD patients, which may permit targeting of preventive and early intervention.
Source: BMC Nephrology - January 14, 2014 Category: Urology & Nephrology Authors: Sonja SuvakovTatjana DamjanovicTatjana PekmezovicJovana JakovljevicAna Savic-RadojevicMarija Pljesa-ErcegovacSlavica RadovanovicDragan SimicSteva PljesaMilos ZarkovicJasmina Mimic-OkaNada DimkovicTatjana Simic Source Type: research